{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T08:29:51Z","timestamp":1793608191629,"version":"4.5.0"},"reference-count":33,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T00:00:00Z","timestamp":1773792000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","cysticfibrosisjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cystic Fibrosis"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.jcf.2026.03.014","type":"journal-article","created":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T12:38:07Z","timestamp":1774355887000},"page":"695-701","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Treatment with elexacaftor\/tezacaftor\/ivacaftor does not alter SpiroNose-derived electronic breath profiles in children with cystic fibrosis"],"prefix":"10.1016","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6610-3756","authenticated-orcid":false,"given":"Elias","family":"Seidl","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7800-5077","authenticated-orcid":false,"given":"Andrew","family":"Zikic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6887-2417","authenticated-orcid":false,"given":"Srdjan","family":"Micic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6956-5312","authenticated-orcid":false,"given":"Rianne","family":"de Vries","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0270-3941","authenticated-orcid":false,"given":"Julie","family":"Avolio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7284-4251","authenticated-orcid":false,"given":"Alexander","family":"Moeller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4057-6592","authenticated-orcid":false,"given":"Felix","family":"Ratjen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0331-9642","authenticated-orcid":false,"given":"Hartmut","family":"Grasemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcf.2026.03.014_bib0001","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1056\/NEJMra2216474","article-title":"Cystic fibrosis","volume":"389","author":"Grasemann","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcf.2026.03.014_bib0002","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/S2213-2600(13)70026-2","article-title":"Early lung disease in cystic fibrosis","volume":"1","author":"Grasemann","year":"2013","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jcf.2026.03.014_bib0003","doi-asserted-by":"crossref","first-page":"18825","DOI":"10.1073\/pnas.0904709106","article-title":"Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770","volume":"106","author":"Van Goor","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jcf.2026.03.014_bib0004","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1164\/rccm.202108-1986OC","article-title":"Clinical effectiveness of elexacaftor\/tezacaftor\/ivacaftor in people with cystic fibrosis: a clinical trial","volume":"205","author":"Nichols","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jcf.2026.03.014_bib0005","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1159\/000538606","article-title":"Improved nutritional outcomes and gastrointestinal symptoms in adult cystic fibrosis patients treated with elexacaftor\/tezacaftor\/ivacaftor","volume":"42","author":"Stastna","year":"2024","journal-title":"Dig Dis"},{"key":"10.1016\/j.jcf.2026.03.014_bib0006","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1176815","article-title":"Real-life impact of highly effective CFTR modulator therapy in children with cystic fibrosis","volume":"14","author":"Olivier","year":"2023","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.jcf.2026.03.014_bib0007","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1164\/rccm.202102-0509OC","article-title":"A phase 3 open-label study of elexacaftor\/tezacaftor\/ivacaftor in children 6 through 11 years of age with cystic fibrosis and at least one F508del allele","volume":"203","author":"Zemanick","year":"2021","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jcf.2026.03.014_bib0008","doi-asserted-by":"crossref","first-page":"9416","DOI":"10.3390\/ijms21249416","article-title":"Potential of the electronic nose for the detection of respiratory diseases with and without infection","volume":"21","author":"Licht","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jcf.2026.03.014_bib0009","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1016\/j.jcf.2023.02.010","article-title":"Exhaled breath profiles to detect lung infection with Staphylococcus aureus in children with cystic fibrosis","volume":"22","author":"Licht","year":"2023","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2026.03.014_bib0010","doi-asserted-by":"crossref","first-page":"431","DOI":"10.3390\/biomedicines12020431","article-title":"Exhaled breath analysis detects the clearance of Staphylococcus aureus from the airways of children with cystic fibrosis","volume":"12","author":"Seidl","year":"2024","journal-title":"Biomedicines"},{"key":"10.1016\/j.jcf.2026.03.014_bib0011","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.jcf.2012.12.010","article-title":"Exhaled molecular profiles in the assessment of cystic fibrosis and primary ciliary dyskinesia","volume":"12","author":"Paff","year":"2013","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2026.03.014_bib0012","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1164\/rccm.202210-1938LE","article-title":"Moving the dial on airway inflammation in response to trikafta in adolescents with cystic fibrosis","volume":"207","author":"Lepissier","year":"2023","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jcf.2026.03.014_bib0013","article-title":"Long-term reductions in inflammation in people with cystic fibrosis treated with elexacaftor\/tezacaftor\/ivacaftor","author":"Sagel","year":"2025","journal-title":"Ann Am Thorac Soc"},{"key":"10.1016\/j.jcf.2026.03.014_bib0014","doi-asserted-by":"crossref","DOI":"10.1177\/17534666251314706","article-title":"Elexacaftor\/tezacaftor\/ivacaftor and inflammation in children and adolescents with cystic fibrosis: a retrospective dual-center cohort study","volume":"19","author":"Pepe","year":"2025","journal-title":"Ther Adv Respir Dis"},{"key":"10.1016\/j.jcf.2026.03.014_bib0015","doi-asserted-by":"crossref","first-page":"2308","DOI":"10.1002\/ppul.26485","article-title":"Impact of Elexacaftor-Tezacaftor-Ivacaftor on lung disease in cystic fibrosis","volume":"58","author":"Gushue","year":"2023","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.jcf.2026.03.014_bib0016","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01817-2017","article-title":"Clinical and inflammatory phenotyping by breathomics in chronic airway diseases irrespective of the diagnostic label","volume":"51","author":"de Vries","year":"2018","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jcf.2026.03.014_bib0017","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1111\/j.1442-9993.2001.01070.pp.x","article-title":"A new method for non-parametric multivariate analysis of variance","volume":"26","author":"Anderson","year":"2001","journal-title":"Austral Ecol"},{"key":"10.1016\/j.jcf.2026.03.014_bib0018","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1111\/j.1541-0420.2005.00440.x","article-title":"Distance-based tests for homogeneity of multivariate dispersions","volume":"62","author":"Anderson","year":"2006","journal-title":"Biometrics"},{"key":"10.1016\/j.jcf.2026.03.014_bib0019","doi-asserted-by":"crossref","DOI":"10.1088\/1752-7163\/aae158","article-title":"Feasibility and diagnostic accuracy of an electronic nose in children with asthma and cystic fibrosis","volume":"13","author":"Bannier","year":"2019","journal-title":"J Breath Res"},{"key":"10.1016\/j.jcf.2026.03.014_bib0020","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0115584","article-title":"Exhaled breath analysis using electronic nose in cystic fibrosis and primary ciliary dyskinesia patients with chronic pulmonary infections","volume":"9","author":"Joensen","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.jcf.2026.03.014_bib0021","article-title":"The impact of cystic fibrosis transmembrane conductance regulator (CFTR) modulators on the pulmonary microbiota","volume":"171","author":"Robertson","year":"2025","journal-title":"Microbiology (N Y)"},{"key":"10.1016\/j.jcf.2026.03.014_bib0022","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1513\/AnnalsATS.202302-165RL","article-title":"Exhaled volatile organic compound profiles differ between children with primary ciliary dyskinesia and cystic fibrosis","volume":"20","author":"Seidl","year":"2023","journal-title":"Ann Am Thorac Soc"},{"key":"10.1016\/j.jcf.2026.03.014_bib0023","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/j.jcf.2020.12.023","article-title":"Extended-culture and culture-independent molecular analysis of the airway microbiota in cystic fibrosis following CFTR modulation with ivacaftor","volume":"20","author":"Einarsson","year":"2021","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2026.03.014_bib0024","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1093\/cid\/ciu944","article-title":"Pseudomonas aeruginosa in cystic fibrosis patients with G551D-CFTR treated with ivacaftor","volume":"60","author":"Heltshe","year":"2015","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jcf.2026.03.014_bib0025","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1164\/rccm.201609-1954OC","article-title":"Restoring cystic fibrosis transmembrane conductance regulator function reduces airway bacteria and inflammation in people with cystic fibrosis and chronic lung infections","volume":"195","author":"Hisert","year":"2017","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jcf.2026.03.014_bib0026","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0164232","article-title":"Throat swabs and sputum culture as predictors of P. aeruginosa or S. aureus lung colonization in adult cystic fibrosis patients","volume":"11","author":"Seidler","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.jcf.2026.03.014_bib0027","first-page":"133","article-title":"Pharmacologic improvement of CFTR function rapidly decreases sputum pathogen density, but lung infections generally persist","author":"Nichols","year":"2023","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jcf.2026.03.014_bib0028","doi-asserted-by":"crossref","DOI":"10.1172\/JCI184171","article-title":"Elexacaftor\/tezacaftor\/ivacaftor\u2019s effects on cystic fibrosis infections are maintained, but not increased, after 3.5 years of treatment","volume":"134","author":"Morgan","year":"2024","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jcf.2026.03.014_bib0029","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1513\/AnnalsATS.202311-1008OC","article-title":"Comparison of longitudinal outcomes in children with primary ciliary dyskinesia and cystic fibrosis","volume":"21","author":"Kinghorn","year":"2024","journal-title":"Ann Am Thorac Soc"},{"key":"10.1016\/j.jcf.2026.03.014_bib0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.rmed.2023.107169","article-title":"Cystic fibrosis and primary ciliary dyskinesia: similarities and differences","volume":"209","author":"Pereira","year":"2023","journal-title":"Respir Med"},{"key":"10.1016\/j.jcf.2026.03.014_bib0031","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.3390\/biom14091189","article-title":"Identification of exhaled metabolites correlated with respiratory function and clinical features in adult patients with cystic fibrosis by real-time proton mass spectrometry","volume":"14","author":"Mustafina","year":"2024","journal-title":"Biomolecules"},{"key":"10.1016\/j.jcf.2026.03.014_bib0032","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/j.jcf.2025.01.004","article-title":"Short-term modification of breathprint by Elexacaftor\/Tezacaftor\/Ivacaftor in a paediatric cohort","volume":"24","author":"Bardin","year":"2025","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2026.03.014_bib0033","doi-asserted-by":"crossref","first-page":"00731","DOI":"10.1183\/23120541.00731-2020","article-title":"Lumacaftor\/ivacaftor changes the lung microbiome and metabolome in cystic fibrosis patients","volume":"7","author":"Neerincx","year":"2021","journal-title":"ERJ Open Res"}],"container-title":["Journal of Cystic Fibrosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199326000810?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199326000810?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T08:13:29Z","timestamp":1793607209000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1569199326000810"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":33,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S1569199326000810"],"URL":"https:\/\/doi.org\/10.1016\/j.jcf.2026.03.014","relation":{},"ISSN":["1569-1993"],"issn-type":[{"value":"1569-1993","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment with elexacaftor\/tezacaftor\/ivacaftor does not alter SpiroNose-derived electronic breath profiles in children with cystic fibrosis","name":"articletitle","label":"Article Title"},{"value":"Journal of Cystic Fibrosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcf.2026.03.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V. on behalf of European Cystic Fibrosis Society.","name":"copyright","label":"Copyright"}]}}